Heather Lounsbury

Statistics

Publications

Citations

657

H-Index

Active since

1995

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Heather Lounsbury is an author at The University of Texas MD Anderson Cancer Center specializing in tyrosine kinase inhibitors, medicine, and btk inhibitors.

Publications per year

1995–2013

Publications

Rates and Mechanism of Fe(II) Oxidation at Nanomolar Total Iron Concentrations

D. Whitney King, Heather Lounsbury, Frank J. Millero · Environmental Science & Technology · 1995 · 347 citations

Natural Sciences, Chemistry, Environmental Sciences +13

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Erica Evans, Richland Tester, Sharon Aslanian et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 219 citations

Medicine, Immunology, Pharmacology +17

Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

Jennifer R. Brown, Jeff P. Sharman, Wael A. Harb et al. · Journal of Clinical Oncology · 2012 · 32 citations

Medicine, Hematology, Pharmacology +17

Synthesis of CMI-977, a Potent 5-Lipoxygenase Inhibitor

Xiong Cai, Mukund S. Chorghade, Aberra Fura et al. · Organic Process Research & Development · 1998 · 27 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,

Erica Evans, Richland Tester, Sharon Aslanian et al. · Blood · 2011 · 20 citations

Medicine, Medicinal Chemistry, Pharmacology +10

1–5 of 6